First Tracks Biotherapeutics (TRAX) Competitors

$20.74 -0.45 (-2.13%)

As of 10:58 AM Eastern

TRAX vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

Should you be buying First Tracks Biotherapeutics stock or one of its competitors? The main competitors of First Tracks Biotherapeutics include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). These companies are all part of the "biotechnology" industry.

How does First Tracks Biotherapeutics compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
60 Degrees Pharmaceuticals $1.01M N/A N/A N/A N/A
First Tracks Biotherapeutics N/A N/A N/A N/A N/A
: First Tracks Biotherapeutics has a consensus target price of $39.43, suggesting a potential upside of 90.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than 60 Degrees Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
First Tracks Biotherapeutics
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
3.00
: In the previous week, First Tracks Biotherapeutics had 13 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 13 mentions for First Tracks Biotherapeutics and 0 mentions for 60 Degrees Pharmaceuticals. First Tracks Biotherapeutics' average media sentiment score of 1.12 beat 60 Degrees Pharmaceuticals' score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
60 Degrees Pharmaceuticals Neutral
First Tracks Biotherapeutics Positive
: Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals N/A N/A N/A
First Tracks Biotherapeutics N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.01M	N/A	N/A	N/A	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Neutral
First Tracks Biotherapeutics	Positive

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	N/A	N/A	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A

Summary

First Tracks Biotherapeutics beats 60 Degrees Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Alpha Tau Medical?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Alpha Tau Medical (NASDAQ:DRTSW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

: In the previous week, First Tracks Biotherapeutics had 13 more articles in the media than Alpha Tau Medical. MarketBeat recorded 13 mentions for First Tracks Biotherapeutics and 0 mentions for Alpha Tau Medical. First Tracks Biotherapeutics' average media sentiment score of 1.12 beat Alpha Tau Medical's score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.
Company Overall Sentiment
First Tracks Biotherapeutics Positive
Alpha Tau Medical Neutral
: First Tracks Biotherapeutics presently has a consensus target price of $39.43, suggesting a potential upside of 90.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe First Tracks Biotherapeutics is more favorable than Alpha Tau Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Tracks Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
3.00
Alpha Tau Medical
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Company Net Margins Return on Equity Return on Assets
First Tracks Biotherapeutics N/A N/A N/A
Alpha Tau Medical N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
First Tracks Biotherapeutics N/A N/A N/A N/A N/A
Alpha Tau Medical N/A N/A N/A N/A N/A

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
Alpha Tau Medical	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Alpha Tau Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Alpha Tau Medical	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Alpha Tau Medical	N/A	N/A	N/A	N/A	N/A

Summary

First Tracks Biotherapeutics beats Alpha Tau Medical on 6 of the 6 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Apollomics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Apollomics (NASDAQ:APLMW) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

: In the previous week, First Tracks Biotherapeutics had 13 more articles in the media than Apollomics. MarketBeat recorded 13 mentions for First Tracks Biotherapeutics and 0 mentions for Apollomics. First Tracks Biotherapeutics' average media sentiment score of 1.12 beat Apollomics' score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.
Company Overall Sentiment
First Tracks Biotherapeutics Positive
Apollomics Neutral
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
First Tracks Biotherapeutics N/A N/A N/A N/A N/A
Apollomics $8.50M N/A N/A N/A N/A
: First Tracks Biotherapeutics presently has a consensus target price of $39.43, suggesting a potential upside of 90.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than Apollomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Tracks Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
3.00
Apollomics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Company Net Margins Return on Equity Return on Assets
First Tracks Biotherapeutics N/A N/A N/A
Apollomics N/A N/A N/A

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
Apollomics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Apollomics	$8.50M	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Apollomics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Apollomics	N/A	N/A	N/A

Summary

First Tracks Biotherapeutics beats Apollomics on 6 of the 7 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to BioVie?

BioVie (NASDAQ:BIVIW) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioVie N/A N/A N/A N/A N/A
First Tracks Biotherapeutics N/A N/A N/A N/A N/A
: In the previous week, First Tracks Biotherapeutics had 13 more articles in the media than BioVie. MarketBeat recorded 13 mentions for First Tracks Biotherapeutics and 0 mentions for BioVie. First Tracks Biotherapeutics' average media sentiment score of 1.12 beat BioVie's score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
BioVie Neutral
First Tracks Biotherapeutics Positive
: Company Net Margins Return on Equity Return on Assets
BioVie N/A N/A N/A
First Tracks Biotherapeutics N/A N/A N/A
: First Tracks Biotherapeutics has a consensus target price of $39.43, suggesting a potential upside of 90.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than BioVie.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioVie
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
First Tracks Biotherapeutics
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	N/A	N/A	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
BioVie	Neutral
First Tracks Biotherapeutics	Positive

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	N/A	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

First Tracks Biotherapeutics beats BioVie on 6 of the 6 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Cardio Diagnostics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Cardio Diagnostics (NASDAQ:CDIOW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
First Tracks Biotherapeutics N/A N/A N/A N/A N/A
Cardio Diagnostics $14.83K N/A N/A N/A N/A
: In the previous week, First Tracks Biotherapeutics had 13 more articles in the media than Cardio Diagnostics. MarketBeat recorded 13 mentions for First Tracks Biotherapeutics and 0 mentions for Cardio Diagnostics. First Tracks Biotherapeutics' average media sentiment score of 1.12 beat Cardio Diagnostics' score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.
Company Overall Sentiment
First Tracks Biotherapeutics Positive
Cardio Diagnostics Neutral
: Company Net Margins Return on Equity Return on Assets
First Tracks Biotherapeutics N/A N/A N/A
Cardio Diagnostics N/A N/A N/A
: First Tracks Biotherapeutics presently has a consensus target price of $39.43, indicating a potential upside of 90.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe First Tracks Biotherapeutics is more favorable than Cardio Diagnostics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Tracks Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
3.00
Cardio Diagnostics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Cardio Diagnostics	$14.83K	N/A	N/A	N/A	N/A

Company	Overall Sentiment
First Tracks Biotherapeutics	Positive
Cardio Diagnostics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Cardio Diagnostics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cardio Diagnostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

First Tracks Biotherapeutics beats Cardio Diagnostics on 6 of the 7 factors compared between the two stocks.

Get First Tracks Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAX vs. The Competition

Export

Metric	First Tracks Biotherapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$449.52M	$6.27B	$12.02B
Dividend Yield	N/A	3.86%	2.74%	5.26%
P/E Ratio	N/A	4.17	29.11	27.10
Price / Sales	N/A	6,716.94	500.58	73.99
Price / Cash	N/A	13.13	43.30	53.90
Price / Book	N/A	78.66	9.66	6.70
Net Income	N/A	-$96.07M	$3.54B	$332.64M
7 Day Performance	-12.27%	1.16%	3.14%	3.50%
1 Month Performance	N/A	3.56%	5.27%	8.31%
1 Year Performance	N/A	49.00%	38.71%	42.31%

First Tracks Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAX First Tracks Biotherapeutics	N/A	$20.74 -2.1%	$39.43 +90.1%	N/A	$0.00	N/A	N/A	N/A	News Coverage Positive News Analyst Forecast
SXTPW 60 Degrees Pharmaceuticals	N/A	$0.05 -0.4%	N/A	-19.3%	$0.00	$1.01M	N/A	2	Gap Up
DRTSW Alpha Tau Medical	N/A	$1.08 -18.8%	N/A	+421.1%	$0.00	N/A	N/A	80	Gap Up
APLMW Apollomics	N/A	$0.02 +10.2%	N/A	+0.0%	$0.00	$8.50M	N/A	59	Gap Up
BIVIW BioVie	N/A	$0.32 -8.5%	N/A	N/A	$0.00	N/A	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAX) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

How does First Tracks Biotherapeutics compare to 60 Degrees Pharmaceuticals?

Summary

How does First Tracks Biotherapeutics compare to Alpha Tau Medical?

Summary

How does First Tracks Biotherapeutics compare to Apollomics?

Summary

How does First Tracks Biotherapeutics compare to BioVie?

Summary

How does First Tracks Biotherapeutics compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

How does First Tracks Biotherapeutics compare to 60 Degrees Pharmaceuticals?

Summary

How does First Tracks Biotherapeutics compare to Alpha Tau Medical?

Summary

How does First Tracks Biotherapeutics compare to Apollomics?

Summary

How does First Tracks Biotherapeutics compare to BioVie?

Summary

How does First Tracks Biotherapeutics compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools